<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726657</url>
  </required_header>
  <id_info>
    <org_study_id>2279</org_study_id>
    <nct_id>NCT04726657</nct_id>
  </id_info>
  <brief_title>Comparison of Two Biphasic Insulin Regimens</brief_title>
  <official_title>Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of&#xD;
      Continuous Glucose Monitoring and New Glycemic Control Indices&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cross-over study of 36 well controlled people with type 2 Diabetes Mellitus who underwent&#xD;
      7-day Continuous Glucose Monitoring with Premixed Human Insulin 30/70 and subsequently with&#xD;
      Biphasic Aspart 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2016</start_date>
  <completion_date type="Actual">February 3, 2020</completion_date>
  <primary_completion_date type="Actual">February 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average blood glucose</measure>
    <time_frame>7 days</time_frame>
    <description>average blood glucose (mg/dl) from continuous glucose monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycated Albumin</measure>
    <time_frame>7 days</time_frame>
    <description>levels of glycated albumin (%) in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>7 days</time_frame>
    <description>levels of fructosamine (Î¼mol/L) in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Insulin requirements</measure>
    <time_frame>7 days</time_frame>
    <description>change in total daily dose of insulin (u)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nocturnal average blood glucose</measure>
    <time_frame>7 days</time_frame>
    <description>change in nocturnal average blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in range</measure>
    <time_frame>7 days</time_frame>
    <description>change in time in range (% and minutes) from continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time above 180</measure>
    <time_frame>7 days</time_frame>
    <description>change in time above 180 (% and minutes) from continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time below 70</measure>
    <time_frame>7 days</time_frame>
    <description>change in time below 70 (% and minutes) from continuous glucose monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Premixed Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premixed Human Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premixed Insulin Analog</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premixed Human Isophane Insulin Suspension + Human Insulin Injection</intervention_name>
    <description>premixed human insulin</description>
    <arm_group_label>Premixed Insulin</arm_group_label>
    <arm_group_label>Premixed insulin</arm_group_label>
    <other_name>premixed human insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premixed Insulin</intervention_name>
    <description>Premixed Insulin Analog Biphasic Aspart 30</description>
    <arm_group_label>Premixed Insulin</arm_group_label>
    <arm_group_label>Premixed insulin</arm_group_label>
    <other_name>Biphasic Aspart 30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  regular attendees of Outpatient Clinic of the Diabetes Centre of the 1st Department of&#xD;
             Internal Medicine of University Hospital in Thessaloniki Greece&#xD;
&#xD;
          -  The patients were on Premixed Human Insulin 30/70 twice daily with or without&#xD;
             metformin&#xD;
&#xD;
          -  baseline HbA1c&lt;7%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the presence of type 1 Diabetes Mellitus&#xD;
&#xD;
          -  stage 4 Chronic Kidney Disease&#xD;
&#xD;
          -  use of antidiabetic medications other than insulin and metformin&#xD;
&#xD;
          -  major cardiovascular event during the last six months&#xD;
&#xD;
          -  acute illness and hospitalization during the last two weeks&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  absence of good metabolic control assessed with self-monitoring of blood glucose&#xD;
             during the week before entering the study (&gt;20% of the measurements &lt;80mg/dl or&#xD;
             &gt;130mg/dl)&#xD;
&#xD;
          -  inability of the patients to understand the study procedures and sign the consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Triantafyllos Didangelos, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA Hospital Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Prof. Triantafyllos Didangelos</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine-Diabetology</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>glycemic control</keyword>
  <keyword>glycated albumin</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <keyword>fructosamine</keyword>
  <keyword>glycated hemoglobin</keyword>
  <keyword>insulin</keyword>
  <keyword>premixed human insulin</keyword>
  <keyword>premixed insulin analog</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

